Our Webinars

Upcoming Webinar

How Equity Research Analysts Value Biotech Companies with Needham & Co

Date: Thursday, October 12, 2023
Time: 1:00PM ET / 10:00AM PT

Moderators:
Laurence Watts
Managing Director, Gilmartin Group

Stephen Jasper
Managing Director, Gilmartin Group

Speakers:
Ami Fadia,
Managing Director, Needham & Co

Serge Belanger,
Managing Director, Needham & Co

How Equity Research Analysts Value Biotech Companies with Needham & Co

Please join Gilmartin Group’s Managing Directors, Laurence Watts and Stephen Jasper, along with guest speakers, Ami Fadia (Managing Director) and Serge Belanger (Managing Director) of Needham & Co. for a webinar on Thursday, October 12th.

Sell-side equity analysts are key to ensuring biotechs have a stock price that reflects their risk, progress and potential. But how do they reach share price targets and buy, hold and sell recommendations? How do analysts calculate your probability of clinical success? What value, if any, do they ascribe to development candidates beyond your lead asset? How do they estimate commercial opportunity, especially for orphan diseases with no approved therapies? Join us for a webinar with Needham’s senior analysts Serge Belanger and Ami Fadia to discuss all these issues and more.

This webinar is intended for corporate audiences only.

Featured Speaker

Ami Fadia
Managing Director,
Needham & Co

Read Biography

Ami Fadia joined Needham and Company in May 2021 covering Biotechnology with a focus on targeted oncology and neuroscience. Prior to joining Needham, Ami spent four years as a Managing Director and Senior Analyst at SVB Leerink and previous to that spent six years at UBS where she most recently held the position of Senior Analyst. Ami also spent time working in industry as Head of Strategy & Operations at Sandoz where she was responsible for building a high performing team responsible for strategic planning, sales force strategy, training, project management, budgeting, and business development. Ami began her career in consulting working at KPMG and then McKinsey & Company in their healthcare practice. Ami holds an MBA from the Kellogg School of Management, her Bachelor’s of Commerce from the Shri Ram College, Delhi University and is a member of the Institute of Chartered Accountants of India.

Serge Belanger
Managing Director,
Needham & Co

Read Biography

Serge Belanger joined Needham & Company in 2009, where he covers the Biotechnology sector. Prior to Needham, Serge worked as a research associate at Fulcrum Global Partners and Susquehanna International Group covering the biotech and specialty pharma healthcare sectors. Previously, Serge was part of Adolor Corporation, a biopharmaceutical company, as a senior research scientist, where he was involved with the discovery and development of novel opioid receptor targeted molecules and non-opioid pain therapeutics. Serge graduated from McGill University with a BSc, Biochemistry/Pharmacology, and an MSc, Pharmacology and Therapeutics. He obtained his MBA in Finance from the Stern School of Business at New York University.

Moderators

Laurence Watts
Managing Director,
Gilmartin Group

Read Biography

Laurence Watts has over 15 years of experience in investor relations, corporate finance, communications, and on Wall Street – including positions in the U.S., London and Singapore. Laurence is focused on the life sciences sector and has been instrumental in building and executing investor relations programs for many biotech companies of various stages.

Prior to joining Gilmartin, Laurence spent four years at Westwicke Partners, advising public and private biotechs on all aspects of their financing strategy and investor relations activities. He has counseled clients on their IPOs, private financings, investor days, clinical trial results, FDA drug approvals, and product launches. Previously he was an equity and debt analyst for a variety of buy side and sell side institutions including JP Morgan, Barclays Capital and members of the ING Group.

Laurence received a BA and MA in economics from Queens’ College, Cambridge University, England.

Stephen Jasper
Managing Director,
Gilmartin Group

Read Biography

Stephen has nearly a decade of healthcare agency experience, specializing in the strategic and tactical implementation of investor relations programs in the biotechnology and specialty pharma sectors.

Prior to joining Gilmartin, Stephen spent seven years at Westwicke ICR, a strategic investor relations firm, advising both private and small/mid cap biotech companies on corporate messaging and capital markets strategy. He has extensive experience in both the pre-IPO advisory process, as well as the development and management of public company IR programs. Prior to that, Stephen worked for Legacy Health Strategies, where he worked alongside leading pharmaceutical and medical device companies to grow their patient engagement platforms.

Stephen received a BA in Economics from the University of California, Santa Barbara.